Madrid, 23 de mayo de 2017
The celebration, at the headquarters of the Senate, of an institutional meeting chaired by the president of the Senate and by the general director of the Basic Portfolio of Services of the National Health and Pharmacy System of the Ministry of Health, where debate was held on the past, the present and the future of generic medicines in particular, and the pharmaceutical industry that develops them, produces and markets them in general, has marked a milestone for the sector, both because of the framework in which it has taken place and because for its participants.Read more
Blog aimed at anyone who wants to express opinions through comments, suggestions and articles of collaborations.
We offer everyone, this place to spread more rigorous knowledge of the generic medicines in the Spanish society.
We create enhanced access to medicines, reducing inequalities, directly leading to improved patient outcomes. We compete, stimulating the medicines industry to innovate. We innovate, enriching patient benefit.
We provide a stable and resilient supply of high-quality medicines, manufactured and developed according to stringent EU regulatory requirements, for Europe’s patients and healthcare providers.
Our high-quality cost-effective medicines account for well over 54% of all prescription medicines used to treat European patients. We are the heart of public health delivery in Europe. We generate cost savings of more than €35bn each year ensuring the viability of Europe’s healthcare systems and enable them to invest in new medicines and other treatments that Europe’s patients increasingly need.
Use of our medicines supports the economic sustainability of Europe’s healthcare systems. We contribute to Europe’s economies, researching, developing and manufacturing in most European countries the majority of medicines used in the EU, sustaining more than 150.000 high skilled, high value direct jobs. As a leading knowledge based industry we will continue to work with Europe’s policy makers, legislators and regulators to create the right environment to support and strengthen the economic sustainability of our industry so that we can continue to contribute to European patients and society.
We build constructive partnerships, focused on a strong and stable collaboration with patients and patient organisations, the EU institutions, governments and regulators, healthcare professionals and others to further enhance public health in Europe.